Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.
2.

Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study.

Verhelst D, Rossert J, Casadevall N, Krüger A, Eckardt KU, Macdougall IC.

Lancet. 2004 May 29;363(9423):1768-71.

PMID:
15172775
3.

[Possible complications of erythropoietin therapy in patients with chronic renal failure].

Pljesa S.

Med Pregl. 2004 May-Jun;57(5-6):254-7. Review. .

PMID:
15503795
4.

Improvement in erythropoieis-stimulating agent-induced pure red-cell aplasia by introduction of darbepoetin-α when the anti-erythropoietin antibody titer declines spontaneously.

Lee H, Yang J, Kim H, Kwon JW, Oh KH, Joo KW, Kim YS, Ahn C, Han JS, Kim S.

J Korean Med Sci. 2010 Nov;25(11):1676-9. doi: 10.3346/jkms.2010.25.11.1676.

6.

Pure red cell aplasia induced by erythropoiesis-stimulating agents.

Pollock C, Johnson DW, Hörl WH, Rossert J, Casadevall N, Schellekens H, Delage R, De Francisco A, Macdougall I, Thorpe R, Toffelmire E.

Clin J Am Soc Nephrol. 2008 Jan;3(1):193-9. doi: 10.2215/CJN.02440607. Review.

7.

[Pure red cell aplasia in erythropoietin therapy in patients with kidney failure].

Opatrný K Jr.

Cas Lek Cesk. 2003;142(12):741-5. Review. Czech.

PMID:
14746223
8.

Pure red-cell aplasia and recombinant erythropoietin.

Gershon SK, Luksenburg H, Coté TR, Braun MM.

N Engl J Med. 2002 May 16;346(20):1584-6; author reply 1584-6. No abstract available. Erratum in: N Engl J Med 2002 Aug 8;347(6):458.

9.

Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin.

Howman R, Kulkarni H.

Nephrol Dial Transplant. 2007 May;22(5):1462-4. No abstract available.

10.

Resolution of epoetin-induced pure red cell aplasia 2 years later, successful re-challenge with continuous erythropoiesis receptor stimulator.

Lim SK, Bee PC, Keng TC, Chong YB.

Clin Nephrol. 2013 Sep;80(3):227-30. doi: 10.5414/CN107456.

PMID:
23298519
11.

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.

Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, Locatelli F, Belknap SM, McKoy JM, Lyons EA, Kim B, Sharma R, Costello S, Toffelmire EB, Wells GA, Messner HA, Yarnold PR, Trifilio SM, Raisch DW, Kuzel TM, Nissenson A, Lim LC, Tallman MS, Casadevall N.

Blood. 2005 Nov 15;106(10):3343-7.

12.

Antiepoetin antibody-related pure red cell aplasia: successful remission with cessation of recombinant erythropoietin alone.

Katagiri D, Shibata M, Katsuki T, Masumoto S, Katsuma A, Minami E, Hoshino T, Inoue T, Tada M, Hinoshita F.

Clin Exp Nephrol. 2010 Oct;14(5):501-5. doi: 10.1007/s10157-010-0318-8.

PMID:
20652821
13.

Rechallenge with intravenous recombinant human erythropoietin can be successful following the treatment of anti-recombinant erythropoietin associated pure red cell aplasia.

Praditpornsilpa K, Tiranathanakul K, Jootar S, Tungsanga K, Eiam-Ong S.

Clin Nephrol. 2014 May;81(5):355-8. doi: 10.5414/CN107690.

PMID:
23110772
14.

Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk.

Cournoyer D, Toffelmire EB, Wells GA, Barber DL, Barrett BJ, Delage R, Forrest DL, Gagnon RF, Harvey EA, Laneuville P, Patterson BJ, Poon MC, Posen GA, Messner HA; Canadian PRCA Focus Group..

J Am Soc Nephrol. 2004 Oct;15(10):2728-34.

15.

A simple screening test for the detection of erythropoietin antibodies.

Meran S, Wonnacott A, Davies M, Ellis R, Phillips A.

Clin Nephrol. 2014 Sep;82(3):215-20. doi: 10.5414/CN107864.

PMID:
23391321
16.

Recovery of native erythropoietin in a patient with erythropoietin-associated pure red cell aplasia.

Prus KM, Al-Rahawan MM.

Pediatr Nephrol. 2014 Jan;29(1):161-2. doi: 10.1007/s00467-013-2580-y. No abstract available.

PMID:
23917451
17.

[Pure red cell aplasia in patients treated with recombinant erythropoietin for anemia due to chronic renal disease].

Miyazaki T, Obana T, Takasaki H, Tanaka M, Yamaji S, Fujimaki K, Fujita H, Kanamori H, Ishigatsubo Y.

Rinsho Ketsueki. 2007 May;48(5):391-6. Japanese.

PMID:
17571584
18.

Acquired pure red cell aplasia in a hemodialyzed patient.

Tanuma Y, Yokoo A, Takashima H.

Int J Urol. 2003 Oct;10(10):550-3.

19.

Pure red-cell aplasia and epoetin therapy.

Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N.

N Engl J Med. 2004 Sep 30;351(14):1403-8.

20.

Anti-erythropoietin antibodies followed by endogenous erythropoietin production in a dialysis patient.

Mattison P, Upadhyay K, Wilcox JE, Moudgil A, Silverstein DM.

Pediatr Nephrol. 2010 May;25(5):971-6. doi: 10.1007/s00467-009-1406-4.

PMID:
20091055
Items per page

Supplemental Content

Support Center